A Case of Cauda Equina Syndrome in Early-Onset Chronic Inflammatory Demyelinating Polyneuropathy Clinically Similar to Charcot-Marie-Tooth Disease Type 1

Seung Eun Lee, M.D., Seung Won Park, M.D., Ph.D., Sam Yeol Ha, M.D., Taek Kyun Nam, M.D.
Department of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea
Department of Neurology, Haeundae Paik Hospital, Inje University, Busan, Korea

To present a case of cauda equina syndrome (CES) caused by chronic inflammatory demyelinating polyneuropathy (CIDP) which seemed clinically similar to Charcot-Marie-Tooth disease type 1 (CMT1). CIDP is an immune-mediated polyneuropathy, either progressive or relapsing-remitting. It is a non-hereditary disorder characterized by symmetrical motor and sensory deficits. Rarely, spinal nerve roots can be involved, leading to CES by hypertrophic cauda equina. A 34-year-old man presented with low back pain, radicular pain, bilateral lower-extremity weakness, urinary incontinence, and constipation. He had had musculoskeletal deformities, such as hammertoes and pes cavus, since age 10. Lumbar spine magnetic resonance imaging showed diffuse thickening of the cauda equina. Electrophysiological testing showed increased distal latency, conduction blocks, temporal dispersion, and severe nerve conduction velocity slowing (3 m/s). We were not able to find genetic mutations at the PMP22, MPZ, PRX, and EGR2 genes. The pathologic findings of the sural nerve biopsy revealed thinly myelinated nerve fibers with Schwann cells proliferation. We performed a decompressive laminectomy, intravenous IgG (IV-IgG) and oral steroid. At 1 week after surgery, most of his symptoms showed marked improvements except foot deformities. There was no relapse or aggravation of disease for 3 years. We diagnosed the case as an early-onset CIDP with cauda equina syndrome, whose initial clinical findings were similar to those of CMT1, and successfully managed with decompressive laminectomy, IV-IgG and oral steroid.

Key Words : Cauda equina syndrome · Chronic inflammatory demyelinating polyneuropathy · Charcot-Marie-Tooth disease · Laminectomy.

INTRODUCTION

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired peripheral neuropathy that affects motor and sensory nerves and usually leads to perivascular endoneurial infiltration by monocytes, macrophages, and lymphocytes. Charcot-Marie-Tooth disease (CMT) is a genetic disorder that affects the peripheral motor and sensory nerve like as CIDP. In CMT type 1 (CMT1) which is the most frequent type of CMT, patients are young at the onset of the disease, and it progresses very slowly. CIDP type 1 occurs in 1–2 per 100000 adults, usually affects the elderly and shows a rapid progression with a relapsing or progressive course. Early-onset CIDP is rarer, 0.5 per 200000 children, and progresses more slowly.

The prognosis and response to treatment are different between CMT1 and CIDP, and it is crucial to distinguish one from the other. Although the hypertrophic cauda equina is uncommon in both CIDP and CMT, it sometimes needs surgical treatment for cauda equina syndrome. Here, we report a rare case of early-onset CIDP with CES, which was clinically similar to CMT, and review the relevant literature.

CASE REPORT

A 34-year-old man presented to our department with low back pain, radiating pain, and weakness of bilateral lower extremities, which had progressed slowly during 3 months, despite medication and physiotherapy. He could not walk and needed a wheelchair to ambulate because of flaccid paraparesis. He also...
had intermittent urinary incontinence and constipation. He showed muscle atrophy in the bilateral lower extremities and a thin body shape. He had foot deformities, hammertoes and pes cavus, since age 10, which made him to walk on his toes (Fig. 1). His family history did not include any incestuous marriages or patients with similar symptoms.

Both lower extremities showed grade 4 weakness. Sensations of pain, temperature, vibration, and proprioception were decreased below the L2 dermatome. The patient showed reduced knee and ankle jerk reflexes on both sides, but no pathologic reflexes.

The spinal MRI revealed a diffuse thickening of the cauda equina, resembling an intradural tumor. This showed low signal intensity in both T1 and T2-weighted images, and slightly inhomogeneous high signal intensity on T1-weighted gadolinium-enhancement (Fig. 2). The brain MRI findings were normal. Hematologic tests for tumor markers (AFP, CEA, PSA, TFT), autoantibodies (ANA, ANCA, SS-A), and viral antibodies (VDRL, HTLV, HIV) were all negative.

On electrophysiological tests, both upper and lower extremities showed conduction blocks, increased distal latency, temporal dispersion, severe reduction in nerve conduction velocity (NCV, 3 m/s), prolonged F-wave latency, and decreased signal amplitude on tibial nerve (Fig. 3). Electromyograms of the lower extremities showed positive sharp waves in the bilateral first dorsal interosseus, vastus lateralis, tibialis anterior, and gastrocnemius muscles. These data suggested a severe, demyelinating-type sensorimotor polyneuropathy.

The patient underwent L2-5 decompressive laminectomy and sural nerve biopsy. Clear cerebrospinal fluid gushed out when the dura was opened, and unusually thick nerve roots were visible. CSF sampling was done. Exploration of the intradural space revealed hypertrophied nerve roots with size variation from normal to about treble size (Fig. 4). Then the dura was closed without patch duraplasty because the intradural space seemed...
to be enough for the swollen roots by virtue of the extra space provided by the decompressive laminectomy. In sural nerve biopsy, light and electron microscope examinations revealed myelinated axon surrounded by proliferated Schwann cells, 'onion bulbs' (Fig. 5). These pathological findings were compatible with chronic demyelinating peripheral neuropathy with remyelination, which can be seen in CMT1 and CIDP31,39,41.

The CSF examination showed normal findings. We performed a genetic examination at autosome 17p12-p11.2 (the PMP 22 gene) and the genes for MPZ, PRX, and EGR2, which frequently contain mutations in CMT patients40. However, we could not find any mutation.

After surgery, the patient showed immediate and marked improvement in pain, sensory deficits, urinary incontinence, and constipation. But, his motor power did not improve immediately after surgery. The patient received high dose intravenous IgG (IV-IgG) (0.4 g/kg/day) for 5 days and oral steroid (prednisolone, 1 mg/kg/day) for 1 week after the surgery. His motor power improved rapidly with the medications, and he could walk independently at 1 week after surgery.

Repeat physical examination and electrophysiological testing performed 1 week after the initial IV-IgG and steroid treatment course showed more quickly improvements in sensory and motor responses. High dose IV-IgG was initiated and followed by monthly for 3 months, but we used once for initial 5 days in our case because high cost40. After discharge, oral steroid therapy (prednisolone, 1 mg/kg/day) was maintained for few weeks and then tapered gently over months40. At one month after discharge, he showed normal motor power of both legs. His foot deformities were not changed. There was no relapse or aggravation of disease during 3 years of follow up.

**DISCUSSION**

Hypertrophy neuropathy that may induce hypertrophic cauda equina include CIDP1,12,23), Guillain-Barré syndrome3), malignant lymphoma30), paraneoplastic syndrome35), sarcoidosis13), CMT4), postirradiation neuropathy13), and various infectious diseases10. In the current case, we suspected the patient suffered from CIDP or CMT according to his symptoms and lab results. Both CIDP and CMT induce demyelinating polyneuropathy of the peripheral nerves, and thus, they may present similar symptoms, such as lower extremity motor weakness31. But, early differential diagnosis is necessary because of different prognosis and response to medication between CIDP and CMT4,14,42.

CIDP is an acquired paralytic disease with high morbidity. It was first introduced to the literature in 197513. The cause of CIDP is unknown, but recent studies support a pathogenesis suggesting an autoimmune disease, possibly an acquired demyelinating neuropathy due to an autoimmune attack on the myelin proteins15,16. It has various clinical manifestations, but its main symptoms are symmetrical sensory deficit and motor weakness27. Also, although rare, it may present pure motor or pure sensory symptoms, tremors, ataxia, and in some cases, foot deformities33). Hypertrophic cauda equina arising from CIDP is quite uncommon11,17,23). This disease may arise at any age, but it usually affects adults with a progressive course over just a few months20,31. The subsequent course can be relapsing and remitting or chronic progressive course with intermittent relapsing21,36.

CMT is a genetic disorder that affects the neuromuscular function. It can be classified into 4 types (CMT1, CMT2, CMTX, CMT4) according to inheritance pattern, molecular diagnostic test, electrophysiological examination, and neuropathology38,39). CMT1 is most common type. Clinical manifestations of CMT1 usually include muscle weakness, pes cavus and hammer toe by demyelination of peripheral nerves31. As in CIDP, hypertrophic cauda equina is quite uncommon in CMT14,30). The disease progresses slowly and usually occurs during the first decade of life31,39,40). Indeed, early-onset CIDP is very rare and similar to CMT1 because of its early onset, slower progression, and foot deformities30,31. So, CMT1 seemed to be more likely the diagnosis of our case because his symptoms included pes cavus, early symptom onset (age 10), and a slow progression (over 20 years). However, the findings of lower extremities were not specific for diagnosis, and may arise in other diseases (peroneal muscular atrophy, Friedreich’s ataxia, myelodysplasia, polionyelitis and so on) can cause foot muscle atrophy25.

Electrophysiological testing is another method for differentiating CIDP from CMT1. Generally, the electrophysiological characteristics of CIDP are as follows: 1) Severely, slowed NCV, less than 10 m/sec; 2) Conduction block and/or temporal dispersion of compound muscle action potentials; 3) Prolonged distal latencies; and 4) Prolonged F-wave latencies14,46. However, NCV in CMT1 shows mild to moderate slowing of nerve conduction, less than 38 m/sec, with no signs of prolonged distal latencies, conduction block, temporal dispersion, or prolonged F-wave latency39). In our case, the patient’s test findings were consistent with CIDP, showing increased distal latency, conduction block, temporal dispersion, prolonged F-wave latency and severe NCV slowing (3 m/s).

In CIDP, a CSF study will show elevated protein level, to more than 45 mg/dL20. However, CSF proteins generally show normal levels in CMT130. In our case, the CSF showed normal protein level, as in CMT1. However, it is hard to differentiate CIDP from CMT1 by examining the CSF, since protein levels may be normal in early-onset CIDP11.

The pathological hallmarks of CMT1 are segmental demyelination and consequent remyelination, the so-called onion bulb27. Demyelination and edema due to inflammatory infiltrates are the key characteristics of CIDP44. Hence, inflammatory infiltrates may indicate CIDP, whereas prominent onion bulb findings likely indicate CMT141. However, onion bulbs without inflammatory infiltrates can be seen in CIDP patients40. Therefore, differential diagnosis of the two diseases by nerve biopsy alone would be insufficient11. In our case, we observed typ-
CMT is an inherited disease with family history, whereas CIDP is an acquired disease. Most of CMT cases are reported to have genetic mutation\(^1\), and it is important for differentiation from CIDP\(^{1,2,12}\). But, we could not see gene mutations in our case for CMT, i.e., PMP 22, MPZ, PRX and EGR2 genes\(^{2,17}\). And we thought the diagnosis of our case more likely as CIDP based on no family history and genetic mutation\(^{21}\).

Corticosteroids, IV-IgG, plasma exchanges, and immunosuppressive drugs have been used in treating CIDP\(^{20}\). Most forms of CIDP show a good response to steroid or IV-IgG, whereas CMT1 does not\(^{22}\). The prognosis of CIDP is variably depends on the response to the treatment\(^{11,12,17,23}\). There have been limited treatment options for CMT1, exercise, orthosis, pain control and some other medications, which did not show significant benefit\(^{20}\). Good therapeutic response to steroids or IV-IgG in CIDP is a useful differentiating point from CMT1\(^{1,3,11,12}\). In our case, favorable response for steroid and IV-IgG might support a diagnosis of CIDP.

Negative gene study, no family history, electrophysiologic test, and good response to steroid and IV-IgG indicated higher possibility of CIDP. In addition to the findings supporting diagnosis of CIDP, we could confirm the diagnosis of early-onset CIDP according to the atypical clinical findings for usual CIDP, early onset, slower progression, and foot deformities.

Motor and sensory deficits due to inflammation respond well to steroid therapy, but CES due to hypertrophic cauda equina shows poor responsiveness to medication\(^{37}\). Hypertrophic cauda equina is known to often result in CES\(^{12,17,23,37}\). In CIDP with CES, decompressive laminectomy is effective for motor and sensory dysfunction\(^{11,12,17,23,37}\). According to previous reports, surgical decompression for hypertrophic nerve root in CMT1 is also effective\(^{20}\). Our case showed prompt recovery from CES after decompressive laminectomy.

**CONCLUSION**

Clinical presentations of early-onset CIDP are similar to those of CMT1. However, it is important to distinguish one from the other because the prognosis and responsiveness to medical treatment differ between them. CES due to hypertrophic cauda equina is a good indication for early decompressive laminectomy.

References

1. Bouchard C, Lacroix C, Planté V, Adams D, Chedrud F, Gaglieshi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. *Neurology* 52: 498-503, 1999
2. Brewerton DA, Sandifer PH, Sweetnam DR. "Idiopathic" pes cavus: an investigation into its aetiology. *Br Med J* 2: 659-661, 1963
3. Briani C, Brannagan TH 3rd, Trojaborg W, Latov N: Neuromuscular chronic demyelinating polyneuropathy. *Neuromuscul Disord* 6: 311-325, 1996
4. Bütefsch C, Gutmann L, Gutmann I.: Compression of spinal cord and cauda equina in Charcot-Marie-Tooth disease type 1A. *Neurology* 52: 890-891, 1999
5. Choi BO, Lee MS, Shin SH, Hwang JH, Choi KG, Kim WK, et al.: Muntational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. *Hum Mutat* 24: 185-186, 2004
6. Connolly AM: Chronic inflammatory demyelinating polyneuropathy in childhood. *Pediatr Neurol* 24: 177-182, 2001
7. Crino PB, Zimmerman R, Laskowitz D, Raps EC, Rostami AM: Magnetic resonance imaging of the cauda equina in Guillain-Barré syndrome. *Neurology* 44: 1334-1336, 1994
8. Dyck PJ, Lambeth EH: Lower motor and primary sensory nerve diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary neuropathies. *Arch Neurol* 18: 603-618, 1968
9. Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambeth EH: Prednisone-responsive hereditary motor and sensory neuropathy. *Mayo Clin Proc* 57: 239-246, 1982
10. Gabreëls-Festen A, Gabreëls F: Hereditary demyelinating motor and sensory neuropathy. *Brain Pathol* 3: 135-146, 1993
11. Ginsberg L, Platts AD, Thomas PK: Chronic inflammatory demyelinating polyneuropathy mimicking a lumbar spinal stenosis syndrome. *J Neurol Neurosurg Psychiatry* 59: 189-191, 1995
12. Goldstein JM, Parks BJ, Mayer PL, Kim JH, Sze G, Miller RG: Nerve root hypertrophy as the cause of lumbar stenosis in chronic inflammatory demyelinating polyradiculoneuropathy. *Muscle Nerve* 19: 892-896, 1996
13. Goodman BP, Driver-Dunckley ED, Leslie KO, Patel AC, Wessels L]: A case of gait unsteadiness—an atypical manifestation of an unusual disease. *Lancet Neurol* 6: 1029-1032, 2007
14. Gorson KC, Chaudhry VV: Chronic inflammatory demyelinating polyneuropathy. *Curr Treat Options Neurol* 1: 251-262, 1999
15. Hahn AF, Bolton CE, Pillay N, Chalk C, Benstead T, Bril V, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. *Brain* 119 (Pt 4): 1055-1066, 1996
16. Hahn AF, Bolton CE, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. *Brain* 119 (Pt 4): 1067-1077, 1996
17. Hahn M, Hirschfeld A, Sander H: Hypertrophied cauda equina presenting as intradural mass: case report and review of literature. *Surg Neurol* 49: 514-518; discussion 518-519, 1998
18. Hartung HP, van der Meché FG, Pollard JD: Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. *Curr Opin Neurol* 11: 497-513, 1998
19. Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al.: Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. *J Neurol Sci* 24: 239-246, 1982
20. Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. *Neurology* 52: 1343-1356, 2005
21. Krajewski K, Turansky C, Lewis R, Garbern J, Hinderer S, Kamholz J, et al.: Correlation between weakness and axonal loss in patients with CMT1A. *Ann Neurol* 53: 890-891, 1999
22. Kotter RM, Burger PC, Tamargo RJ: Hypertrophic neuropathy of the cauda equina: myelographic, CT myelographic, and MR appearance. *AJNR* 21: 57-63, 2001
23. Krajeski K, Turansky C, Lewis R, Garbern J, Hinderer S, Kamholz J, et al.: Correlation between weakness and axonal loss in patients with CMT1A. *Ann Neurol* 53: 890-891, 1999
24. Kretzer RM, Burger PC, Tamargo RJ: Hypertrophic neuropathy of the cauda equina: case report. *Neurosurgery* 54: 515-518; discussion 518-519, 2004
25. Lewis RA: Chronic inflammatory demyelinating polyneuropathy and other immune-mediated demyelinating neuropathies. *Semin Neurol* 25: 217-228, 2005
25. Lins H, Kanakis D, Dietzmann K, Wallesch CW, Mawrin C: Paraneoplastic necrotizing myelopathy with hypertrophy of the cauda equina. J Neurol 250: 1388-1389, 2003

26. Maisonobe T, Chassande B, Vérin M, Jouni M, Léger JM, Bouche P: Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiologic study of 93 patients. J Neurol Neurosurg Psychiatry 61: 36-42, 1996

27. McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiologic study of 92 cases. Brain 110 (Pt 6): 1617-1630, 1987

28. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 46: 910-913, 1999

29. Menkes DL, Hood DC, Ballestros RA, Williams DA: Root stimulation improves the detection of acquired demyelinating polyneuropathies. Muscle Nerve 21: 298-308, 1998

30. Nevo Y: Childhood chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol 2: 169-177, 1998

31. Pareyson D: Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurol Sci 25: 72-82, 2004

32. Planté-Bordeneuve V, Parman Y, Guiochon-Mantel A, Ali Y, Deymeer F, Serdaroglu P, et al.: The range of chronic demyelinating neuropathy of infancy: a clinico-pathological and genetic study of 15 unrelated cases. J Neurol 248: 795-803, 2001

33. Pollard JD: Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 15: 279-283, 2002

34. Prineas JW: Pathology of inflammatory demyelinating neuropathies. Baillieres Clin Neurol 3: 1-24, 1994

35. Rosen SA, Wang H, Cornblath DR, Uematsu S, Hurko O: Compression syndromes due to hypertrophic nerve roots in hereditary motor sensory neuropathy type I. Neurology 39: 1173-1177, 1989

36. Said G: Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 16: 293-303, 2006

37. Schady W, Goulding PJ, Lecky BR, King RH, Smith CM: Massive nerve root enlargement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 61: 636-640, 1996

38. Shy ME: Charcot-Marie-Tooth disease: an update. Curr Opin Neurol 17: 579-585, 2004

39. Shy ME, Lüpski JR, Chance PF, Klein CJ, Dyck PJ: Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features in Dyck PJ, Thomas PK (eds): Peripheral Neuropathy, ed 4. Philadelphia: Elsevier Saunders, 2005, pp1623-1658

40. Thomas PK, King RH, Small JR, Robertson AM: The pathology of charcot-marie-tooth disease and related disorders. Neuropathol Appl Neurobiol 22: 269-284, 1996

41. Uncini A, Parano E, Lange DJ, De Vivo DC, Lovelace RE: Chronic inflammatory demyelinating polyneuropathy in childhood: clinical and electrophysiologic features. Childs Nerv Syst 7: 191-196, 1991

42. Young P, De Jonghe P, Stögbauer F, Rutterfass-Bahloul T: Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev (1): CD006052, 2008